IDSA News - 02/01/2008  (Plain Text Version)

Return to Graphical Version

 

In this issue:
•  Meeting on Key Issues in TB Drug Development
•  CDC Survey Shows Less Effective Flu Medications Still Used
•  EIN: Decolonize MRSA Patients or Not?
•  Health Alerts, Drug Approvals, Recalls, Adverse Events
•  In the IDSA Journals
•  Multidrug-resistant Staph Reported among MSM
•  CMS Requires NPI on Claims Starting March 1
•  Europe Reports High Percentage of Oseltamivir-resistant Influenza Virus
•  IDSA Policy & Advocacy Update
•  Welcome, New IDSA Members!

 

Meeting on Key Issues in TB Drug Development

May 5 - 6, 2008, New Delhi, India

Open Forum 3 is the third in a series of two-day Open Forum meetings aiming to discuss key issues in tuberculosis (TB) drug development, with a special focus on regulatory affairs. The Forum will include sessions on the current global TB drug development portfolio, key issues in the critical path to TB drug registration, designing pivotal trials, conducting registration trials in high burden countries, challenges in TB drug development for resistant disease, and developing regimens containing multiple novel agents. These meetings are designed to bring together regulators, TB drug developers and other interested stakeholders such as TB care providers, public health policy-makers, and community advocates from both major industrialized and high burden countries.

The meeting is being organized and sponsored by Global Alliance for TB Drug Development (TB Alliance), the Bill & Melinda Gates Foundation, The Stop TB Partnership Working Group on New Drugs, and Treatment Action Group.

The meeting is supported in part by unrestricted educational grants from AstraZeneca, Bayer, GlaxoSmithKline and Johnson & Johnson/Tibotec.

Pre-registration is required and registration is free. For more information about this event and to register, please go to: http://www.tballiance.org/events/openforum3.php.

For inquiries, please contact the Conference Secretariat at rsvp@tballiance.org.